Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Nimotuzumab|DRUG: docetaxel|DRUG: capecitabine
Sponsor: Chinese Academy of Medical Sciences
Collaborators: Biotech Pharmaceutical Co., Ltd.